The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

Cpn1  -  carboxypeptidase N, polypeptide 1

Rattus norvegicus

Synonyms: CPN, Carboxypeptidase N catalytic chain, Carboxypeptidase N polypeptide 1, Carboxypeptidase N small subunit
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Cpn1

  • The possible correlation between the severity of CPN and the incidence of pheochromocytoma may influence interpretation of carcinogenic effects observed at this site [1].
  • Serum CPN concentrations were not significantly increased in rats with primary sarcomas (mean = 0.38 g per liter) (S.D. +/- 0.05), versus 0.35 g per liter (S.D. +/- 0.04) in controls [2].
  • Many chemicals are known to exacerbate the severity of CPN to an advanced stage, and this interaction between chemical and CPN can result in a small increase in the incidence of renal adenomas in 2-year carcinogenicity bioassays [3].
 

High impact information on Cpn1

  • Since CPN does not interact significantly with hepatocytes, its presence in bile suggests transcytosis via the biliary epithelium [4].
  • Using an antibody to CPN which reacts also with AsCPN, we found about 70% of the bile radioactivity to be immunoprecipitable following injections of either glycoprotein, indicating that a fraction of these copper proteins had entered the bile essentially unmodified [4].
  • In addition to Lys-Lys-BK (B1087), which is partially resistant to ACE, [Hyp3,Phe8-r-Arg9]BK (B7642) was completely resistant to ACE, CPN, and the unidentified plasma activity (1.9 +/- 0.3 nmol/min/ml), and D-Arg0[Hyp3,Phe8-r-Arg9]BK (B7644) was resistant to all plasma hydrolysis, including APP (less than 0.2 nmol/min/ml) [5].
  • In addition to angiotensin I converting enzyme (ACE; EC 3.4.15.1) and carboxypeptidase N (CPN; EC 3.4.17.3), other peptidases contribute to bradykinin (BK) degradation in plasma [6].
  • Useful modifications compatible with agonistic activity included D-Arg0 (protects against APP), D-N-methyl-Phe7 and dehydro-Phe5 (protect against ACE), and erythro-phenylserine or erythro-amino-phenyl-butyric acid at position 8 (protect against ACE and CPN) [7].
 

Chemical compound and disease context of Cpn1

 

Biological context of Cpn1

  • CPN (chronic progressive nephropathy) is a spontaneous age-related disease that occurs in high incidence in the strains of rat commonly used in preclinical toxicology studies, exhibiting a male predisposition [3].
 

Associations of Cpn1 with chemical compounds

  • Carboxypeptidase R (EC 3.4.17.20) (CPR) and carboxypeptidase N (EC 3.4.17.3) (CPN) cleave carboxy-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities [8].
  • With both doses of rhIL-1 beta, iron, albumin, CPN, and lysine were significantly decreased whereas alpha 2-globulin, urea, and creatinine were significantly increased 12 hr after administration [9].
  • Treatment with oxyphenylbutazone and hydrocortisone failed to inhibit the raised serum CPN levels [10].
  • Serum ceruloplasmin (CPN) levels under different types of acute and chronic experimentally-induced inflammatory conditions in rats and the effect of anti-inflammatory drugs viz. oxyphenylbutazone and hydrocortisone on serum CPN levels were investigated [10].
 

Analytical, diagnostic and therapeutic context of Cpn1

  • To elucidate the complex role of CPN and CPR in vivo, studies in animal models will be essential [11].
  • Maximum concentrations of serum CPN occurred at 31 to 34 days after tumor transplantation, (mean = 0.56 +/- 0.05 g per liter), equivalent to 1.6 +/- 0.2 times the initial CPN concentrations in serums obtained prior to treatment (P less than 0.001) [2].
  • The precise etiology of CPN and the mechanism(s) underlying its pathogenesis remain unknown, but the long-standing assumption that glomerular dysfunction is the primary basis is challenged in the light of contemporary developments in understanding filtration and postglomerular cellular processing of albumin [3].

References

  1. The association between severe nephropathy and pheochromocytoma in the male F344 rat -- the National Toxicology Program experience. Nyska, A., Haseman, J.K., Hailey, J.R., Smetana, S., Maronpot, R.R. Toxicologic pathology. (1999) [Pubmed]
  2. Serum ceruloplasmin concentrations in rats with primary and transplanted sarcomas induced by nickel subsulfide. Sunderman, F.W., Trudeau, E.A., Horak, E., Mitchell, J.M., Allpass, P.R. Ann. Clin. Lab. Sci. (1979) [Pubmed]
  3. A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Hard, G.C., Khan, K.N. Toxicologic pathology. (2004) [Pubmed]
  4. Origins of biliary copper. Kressner, M.S., Stockert, R.J., Morell, A.G., Sternlieb, I. Hepatology (1984) [Pubmed]
  5. Depressor action of bradykinin agonists relative to metabolism by angiotensin-converting enzyme, carboxypeptidase N, and aminopeptidase P. Ahmad, S., Ward, P.E. Proc. Soc. Exp. Biol. Med. (1992) [Pubmed]
  6. Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P. Ward, P.E., Chow, A., Drapeau, G. Biochem. Pharmacol. (1991) [Pubmed]
  7. Structural requirements for B2-agonists with improved degradation stability. Dendorfer, A., Wagemann, M., Reissmann, S., Dominiak, P. Immunopharmacology (1999) [Pubmed]
  8. Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Kato, T., Akatsu, H., Sato, T., Matsuo, S., Yamamoto, T., Campbell, W., Hotta, N., Okada, N., Okada, H. Microbiol. Immunol. (2000) [Pubmed]
  9. Recombinant human interleukin-1 beta decreases serum carboxypeptidase N and modifies serum amino acid concentrations in rats. Dayer, J.M., Hampai, A., Schmidt, M., Winistörfer, B., Mirkovitch, V., Roth, M. Exp. Mol. Pathol. (1989) [Pubmed]
  10. Role of ceruloplasmin in inflammation: increased serum ceruloplasmin levels during inflammatory conditions and its possible relationship with anti-inflammatory agents. Deshmukh, V.K., Raman, P.H., Dhuley, J.N., Naik, S.R. Pharmacological research communications. (1985) [Pubmed]
  11. Heat stability of carboxypeptidase R of experimental animals. Komura, H., Shimomura, Y., Yumoto, M., Katsuya, H., Okada, N., Okada, H. Microbiol. Immunol. (2002) [Pubmed]
 
WikiGenes - Universities